stoxline Quote Chart Rank Option Currency Glossary
ACADIA Pharmaceuticals Inc. (ACAD)
24.78  -0.07 (-0.28%)    02-23 16:00
Open: 24.93
High: 25.23
Volume: 1,404,120
Pre. Close: 24.85
Low: 24.6
Market Cap: 4,068(M)
Technical analysis
2024-02-23 4:34:44 PM
Short term     
Mid term     
Targets 6-month :  31.64 1-year :  34.21
Resists First :  27.09 Second :  29.29
Pivot price 25.39
Supports First :  23.54 Second :  19.58
MAs MA(5) :  24.89 MA(20) :  25.71
MA(100) :  25.09 MA(250) :  24.36
MACD MACD :  -0.7 Signal :  -0.7
%K %D K(14,3) :  39.7 D(3) :  37.2
RSI RSI(14): 37.7
52-week High :  33.99 Low :  17.7
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ACAD ] has closed above bottom band by 22.2%. Bollinger Bands are 53.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.28 - 25.42 25.42 - 25.58
Low: 24.2 - 24.36 24.36 - 24.53
Close: 24.48 - 24.76 24.76 - 25.06
Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Headline News

Sun, 25 Feb 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even - Yahoo Finance

Sun, 25 Feb 2024
Shareholders in ACADIA Pharmaceuticals (NASDAQ:ACAD) are in the red if they invested three years ago - Simply Wall St

Sun, 25 Feb 2024
ACADIA Pharmaceuticals (ACAD) Set to Announce Earnings on Tuesday - AmericanBankingNEWS

Fri, 23 Feb 2024
Healthcare of Ontario Pension Plan Trust Fund Has $4.94 Million Stock Holdings in ACADIA Pharmaceuticals Inc ... - MarketBeat

Thu, 22 Feb 2024
ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses - GlobeNewswire

Wed, 21 Feb 2024
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 164 (M)
Shares Float 109 (M)
Held by Insiders 0.4 (%)
Held by Institutions 99.8 (%)
Shares Short 7,680 (K)
Shares Short P.Month 7,910 (K)
Stock Financials
EPS -0.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.21
Profit Margin -23.6 %
Operating Margin -27.3 %
Return on Assets (ttm) -15.7 %
Return on Equity (ttm) -37.8 %
Qtrly Rev. Growth 62 %
Gross Profit (p.s.) 0
Sales Per Share 3.84
EBITDA (p.s.) -0.92
Qtrly Earnings Growth 0 %
Operating Cash Flow -93 (M)
Levered Free Cash Flow -44 (M)
Stock Valuations
PE Ratio -27.24
PEG Ratio 0.2
Price to Book value 11.21
Price to Sales 6.43
Price to Cash Flow -43.97
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android